

REVIEW

Open Access



# Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

Jean-François Rossi<sup>1,2,3\*</sup> , Patrice Céballos<sup>3</sup> and Zhao-Yang Lu<sup>4</sup>

## Abstract

Cancer cell growth is associated with immune surveillance failure. Nowadays, restoring the desired immune response against cancer cells remains a major therapeutic strategy. Due to the recent advances in biological knowledge, efficient therapeutic tools have been developed to support the best bio-clinical approaches for immune precision therapy. One of the most important successes in immune therapy is represented by the applicational use of monoclonal antibodies, particularly the use of rituximab for B-cell lymphoproliferative disorders. More recently, other monoclonal antibodies have been developed, to inhibit immune checkpoints within the tumor microenvironment that limit immune suppression, or to enhance some immune functions with immune adjuvants through different targets such as Toll-receptor agonists. The aim is to inhibit cancer proliferation by the diminishing/elimination of cancer residual cells and clinically improving the response duration with no or few adverse effects. This effect is supported by enhancing the number, functions, and activity of the immune effector cells, including the natural killer (NK) lymphocytes, NKT-lymphocytes,  $\gamma\delta$  T-lymphocytes, cytotoxic T-lymphocytes, directly or indirectly through vaccines particularly with neoantigens, and by lowering the functions of the immune suppressive cells. Beyond these new therapeutics and their personalized usage, new considerations have to be taken into account, such as epigenetic regulation particularly from microbiota, evaluation of transversal functions, particularly cellular metabolism, and consideration to the clinical consequences at the body level. The aim of this review is to discuss some practical aspects of immune therapy, giving to clinicians the concept of immune effector cells balancing between control and tolerance. Immunological precision medicine is a combination of modern biological knowledge and clinical therapeutic decisions in a global vision of the patient.

**Keywords:** Precision therapy, Immunotherapy, NK lymphocytes, T-lymphocytes, Dendritic cells, Vaccination, Cancer

## Introduction

The development of a disease in each individual is an inherently heterogeneous process that is determined by a unique combination of exogenous and endogenous factors. Molecular pathological epidemiology (MPE) provides a novel insight in underlying the causal mechanisms of a disease, to find an approach for individualized treatment [1–3]. According to the definition of the National Institutes of Health, precision medicine is “an emerging approach for disease treatment and prevention that takes

into account individual variability in genes, environment, and lifestyle for each person” [4]. Precision medicine has become a generic term referring to techniques that evaluate either the host or the disease to enhance the likelihood of beneficial treatment outcomes from medical interventions [5]. Immune precision medicine is not only when immune therapy merges with precision medicine [6], but it also encompasses a better biological understanding of the tumor cells and its microenvironment; a better evaluation of the mechanisms implicated in immune control, immune senescence, and the different crossroads within a bio-clinical overview, in order to define a personalized therapeutic strategy [7]. Based on the concept of immune surveillance, the immune system

\*Correspondence: jeanfrancoisrossi@me.com

<sup>1</sup> Institut Sainte Catherine, 84918 Avignon, France

Full list of author information is available at the end of the article



should ideally work to eradicate cancer cells [8, 9]. However, tumors are still able to evade this system, leading to immune surveillance failure [10]. Cancer immunotherapy can be envisaged by the following four strategies to block the tumor immune evasion and to restore immune surveillance: (1) increasing the number of immune effector cells (IECs) by infusing ex vivo expanded IECs to improve the effector/tumor ratio; (2) increasing the IECs recognition affinity to tumor antigens or tumor-associated antigens (TAA); (3) improving the homing of killer IECs to the cancer cells through its microenvironment by amplifying their trafficking and homing mechanisms; (4) blocking the immune suppression ability of cancer cells. These strategies may restore the immune surveillance by not only killing the tumor cells but also preventing the emergence of new tumor cell clones which may result due to gene mutation after anti-tumor therapy.

Immune therapy was initiated in the early nineties through attenuated bacteria to create inflammatory stimuli [11]. After the Second World War, allogeneic transplantation (AlloT) was developed as a rescue strategy for radiation-induced bone marrow injury and was then introduced in the treatment for leukemias [12]. The presentation of the new immune component from the donor to a recipient made it possible to control the tumoral residual disease. The efficacy of AlloT has demonstrated in hematological malignancies, particularly for acute leukemias, and post-transplantation, where the administration of donor lymphocyte infusion (DLI) has improved the efficacy of immune therapy [13]. However, despite a modest therapeutic benefit was observed when specifically-activated and amplified immune cells were administered in certain solid tumors, AlloT failed to demonstrate major responses in solid cancers [14]; probably due to the poor accessibility of IEC to target the cancer cells. The development of immunological research has lead clinicians to directly use IEC-drugs that have been activated ex vivo to treat malignancies, and different immune adjuvants to reinforce cellular activity or inhibit specific immune checkpoints.

The aim of this review is to discuss how and when to use the different available immune therapeutic tools to support the activation, amplification, or administration of active IEC against the cancer cells.

### **Pretreatment considerations: asking the right questions**

A personalized and complete bio-clinical evaluation of the functional IEC is mandatory to guide the correct therapeutic choice, as to whether reinforce the IEC to kill cancer cells or to lower the number of those IEC which promotes cancer cell evasion. For making the right therapeutic choice, the following questions should

be taken into consideration: (1) how to improve the patient's care based on the evaluation of the patient's immune status; (2) how to maintain an efficient IEC number to cancer cells ratio, (3) whether is it necessary to infuse IEC-drugs or to stimulate the patients' IEC, (4) what is the anti-tumor activity of these IEC, their homing and presence within the cancer microenvironment; (5) how to lower the unfavorable mechanisms, particularly those that favor cancer cell growth and (6) what would be the right timing for treatment administration, and which combination or sequence of drug infusion to implement. Below, we discuss the different aspects that need to consider before giving immunotherapy.

## **Evaluation of the different cancer cell aspects**

### **Cancer microenvironment**

The interaction between tumor cells and non-tumor cells mediated by cell-cell contact and soluble molecules, such as cytokines, chemokines, growth factors, and enzymes create the cancer microenvironment [15, 16]. This is a heterogeneous medium containing both activating and blocking cells which target the tumor. We observed that IEC localization has an impact on the prognosis of patients having follicular lymphoma (FL), particularly for CD8 T-cells and T regulators (Treg or FoxP3 positive cells) [17]. In that study, the interfollicular CD8/FOXP3 positive cell ratio was significantly higher in patients with histological grade 3 tumors (2.04 vs. 1.63) and had a high-risk FL international prognostic index (FLIPI) (2.99 vs. 1.53) compared to those with grade 1-2 tumors or a low-intermediate FLIPI index. Similar results were obtained for the follicular CD8/FOXP3 positive cell ratio. The interfollicular CD8/FOXP3 ratio was found to have prognostic value (5-year overall survival [OS] of 82% vs. 59% for a ratio of  $\pm 1.68$ ). In addition, an interfollicular FOXP3 positive cell number of more than 86 cells/mm<sup>2</sup> was correlated with a more favorable outcome ( $P = 0.03$ ) [17]. So, modulation of these IEC could be achieved at a clinical level by administering cytotoxic T-cells or lowering Tregs by short immune suppression. The biological/chemical status of the cancer microenvironment is associated with immune response and clinical prognosis. This includes cycling hypoxia with spatial and temporal fluctuations in oxygen levels that are correlated to neo-vascularization, chemoresistance, and tumor metastasis [18, 19]. Different information from the cancer microenvironment, particularly the equilibrium state between cytotoxic/suppressive cells and their localization and functional status are necessary information for further precise immunomedical biological algorithms.

### Cancer cells antigens expression

Self-produced proteins produced in the body are non-antigenic due to self-tolerance. Proteins produced by tumors have abnormal structures and act as tumor antigens. When these are present only on tumor cells, they are known as tumor-specific antigen (TSA) and when present on both tumor cells and some normal cells, they are known as TAA. The major histocompatibility complex class II (MHCII) is responsible for presenting these tumor-derived antigen peptides to the T-lymphocytes [20]. Targeting these cancer antigens is the key for anti-tumor immune therapy and for increasing efficacies, identifying the density of these antigenic peptides is important.

### Evaluation of tumor mass and its reduction possibility

Tumor mass evaluation became a major parameter for patient follow-up in the context of clinical research as well as in standard medicine. A great number of tools have been developed to perform such analysis, from standard medical imaging to the evaluation of minimal residual disease by flow cytometry or next-generation sequencing. Dynamic evaluation of the tumor mass is a major parameter to define the right choice of the immune tools and the right time to use them. This is based on the balance of efficiency between the number of cancer cells and the number and efficacy of killer IECs [21]. Immune therapy was generally used after tumor mass debulking to control residual disease. Nowadays, due to the efficacy of the new immune tools including IEC, the therapeutic choice needs to be guided by this new concept, the balance of efficiency between tumor mass and the number of IEC, needing dynamic evaluation.

### Cancer immune-evasion mechanisms

The mechanisms by which cancer cells evade the immune system should be thoroughly considered, and to include the evaluation of the functional status of the cancer cells, their proliferative and metastatic mechanisms, their metabolic status, the MHC expression which is responsible for displaying the tumor-derived antigen peptides on the antigen-presenting cells (APCs), and the mutanome that transforms mutated tumoral proteins into neoantigens, leading to immunome [22–24]. The aim is to reinforce the immune system to destroy the cancer cells by blocking their protective mechanisms. The Food and Drug Administration (FDA) has approved the anti-programmed death-1 (PD-1) monoclonal antibody (mAb), pembrolizumab, for any solid tumor overexpressing the PD-1 receptor ligand, which is associated to microsatellite instability-high, a condition of genetic hypermutability which generates mutated proteins which are not

recognized as self-proteins and represent neoantigens [25]. It was the first time that a tissue-agnostic drug was approved by the FDA based on tumor genetics and may represent conditions to combine vaccination and immune checkpoint inhibitors.

### Evaluation of the patient immune system

The first step of precision immune medicine is to evaluate the functions of the patients' immune system, with the aim of determining its ability to respond to therapeutic interventions. These include the assessments of the genetic context of the patient, particularly the auto-immune processes that may require gene polymorphism analysis, the evaluation of immunosenescence based on the immune functions such as tryptophan metabolism and cytokine production, and immune exhaustion including the evaluation of the potential consequences of chemotherapeutic or targeted drugs on the patient's condition. Further, the existing inflammatory processes within the patient may have a major impact on immune responses, immune resistance, and metastatic process through activation of neovascularization and myeloid-derived suppressor cells in the cancer microenvironment [26]. They may have developed upon the interactions between cancer cells and their microenvironment, microbiota or due to existing co-morbidities [27, 28]. The C-reactive protein (CRP) can be used to evaluate the inflammation condition [29] and may provide hints on the immune status of the patients.

The metabolic status of the immune cells also changes under diverse conditions and is associated with modified functions of the T-lymphocytes [30]. MHC-I modulation due to the changes in tumor cell metabolism regulates the tumor sensitivity to cytotoxic T-lymphocytes (CTL) and to natural killer lymphocytes (NK) through extracellular-signal-regulated kinase 5 (ERK5) expression that modulates MHC-I complex expression and influences the T- and NK activities [31]. Standard evaluation by flow cytometry of the circulating IEC is currently used but is poorly correlated to the immune status within the cancer microenvironment. The evaluation of cellular specific response against TSA after vaccine therapy could be performed by demonstrating a restricted immune T-cell response including T-cell receptor (TcR) rearrangement, ELISpot or other techniques [32].

### Choosing IEC targeting

The products to interfere in anti-tumor effect supported by the immune system can be classified into cell-containing products and non-cell-containing products. Non-cell-containing products include monoclonal antibodies (mAbs), cytokines and cytokine inhibitors, some

chemical immune modulators, and anti-tumor vaccines pulsed with different adjuvants [33–38].

Immune effector cells, particularly  $\alpha\beta$ T-,  $\gamma\delta$ T-, NK-, and NKT-lymphocytes, are immune cells that mainly support cancer immune surveillance. In cancer patients, autologous IECs are generally inactive because the activity and/or the number of these cells are reduced by tumor cells in the tumor microenvironment. One therapeutic possibility is to improve the activity or the number of IEC to bypass the mechanisms of immune failure, by using immune modifiers or by switching specific antigen presentation. Likewise, Allo-innate cells, including NK lymphocytes could be used because of their non-MHC recognition mechanism and stress protein expression, such as the heat shock proteins (HSP), in tumor cells.

In the early eighties, clinicians used cytokines, such as interleukin (IL) 2 [39], to expand autologous immune cells, particularly T-lymphocytes [40–42]. Autologous lymphocyte-activated killer cells (LAK) and cytokine-induced killer (CIK) lymphocytes, derived from the peripheral blood of the patients can be expanded *ex vivo*, and then re-infused into them [43]. In this way, the tissues surrounding the cancer cells were more likely to contain a larger number of immune cells, particularly tumor-infiltrating lymphocytes (TIL) with anti-cancer activity. TILs taken from tumor tissue obtained after biopsy were then considered as antigen-specific T-lymphocytes, and were cultured and expanded in the lab before their re-infusion [44]. However, the major problem of such a product was the uncontrolled cell heterogeneity including both specific cytotoxic cells and Tregs that may favor tumor progression. This cellular heterogeneity may explain the lack of major clinical benefit. Specific anti-cancer eradication is supported by the recognition of TAA presented by APCs that triggers specific T-lymphocytes [45–48]. Epigenetic modifying agents such as deacetylase inhibitors may modulate TAA expression and the release of mutated proteins representing neoantigens which may promote vaccination therapy [49, 50]. Recent advances in active cellular therapies have shown that by genetically modifying the T-lymphocytes, their efficacy through the antigen receptor (TCR) or tumor cell linkage via chimeric antigen receptor (CAR) could be enhanced [51]. As such, modern technology is paving the path to amplify the immune system, which can become better equipped with more effective IEC against cancer cells. Below, we review and discuss the different IEC.

#### $\alpha\beta$ T-lymphocytes

Cytotoxic T-lymphocytes expressing  $\alpha\beta$  TcR represent the main subset of circulating lymphocytes in which the MHC-restricted antigen recognition is mandatory for their activity. LAK, TIL and some CIK lymphocytes

mentioned above are mainly  $\alpha\beta$  T lymphocytes. Autologous CTL, being predominantly  $\alpha\beta$  T-lymphocytes, for instance, the CAR-T lymphocytes and TcR-engineered T-lymphocytes, have been genetically engineered to specifically target and to destroy cancer cells.


CAR-T lymphocytes were developed by generating a genetic construct that encodes the antigen-binding region of a mAb and the intracellular components of the TcR that activate signals upon binding to target cell surface antigens. Different generations of CAR-T lymphocytes were developed based on the combination of the antigen-binding domains of the heavy and light chains of antibodies that are fused to the CD3- $\zeta$  intracellular signaling domain and co-stimulatory molecules to enhance the avidity of T-lymphocytes for antigens [51]. Using the CAR-T lymphocytes as a therapeutic strategy has been associated with clinical success in hematological malignancies including acute myeloid leukemias by using chimeric CD123 [the IL3-R $\alpha$  chain] receptor-modified T-lymphocytes [52], chronic lymphocytic leukemia (CLL) [53], pre-B acute lymphoblastic leukemia with CD19, and other lymphoid malignancies [54]. However, in B-acute lymphocytic leukemia, the median event-free survival was 6.1 months, and 26% of patients developed severe cytokine release syndrome [55] with fatal outcome observed [56]. Recently, kinetics and biomarkers have been identified, with the description of a classification-tree algorithm to guide studies and to propose therapy including anti-IL-6 [57, 58]. There have been more than 70 clinical trials with CAR-T lymphocytes referred at the National Institute of Health (NIH) [59]. The response rate superior to 80% observed in refractory lymphoid malignancies has led several pharmaceutical companies in Western countries and China to invest in the CAR-T strategies [60]. In contrast, the TcR engineering is based on the ability to genetically modify lymphocytes to express TcR with specificity against a chosen antigen that allows these chimeric TcR-T cells to target tumor cells with MHC class I-restricted antigen peptide presentation. This methodology was first used with MART-1 antigen in melanoma but demonstrated a lower response rate (13%) as compared to that observed with TIL (51–72%) [61].

#### $\gamma\delta$ T-lymphocytes

$\gamma\delta$ T-lymphocytes represent a minor subset (10%) of circulating lymphocytes, with a dominant V $\gamma$ 9V $\delta$ 2 TcR cell subpopulation, that recognizes the endogenous pool of isopentenyl pyrophosphate.  $\gamma\delta$ T-lymphocytes are implicated in anti-viral and anti-tumor responses, and in modulating immune response [62–64]. Like NK lymphocytes,  $\gamma\delta$ T-lymphocytes respond to stimulation by stress- and/or infection-induced ligands. Usually, these ligands are weakly- or not-expressed, and are up-regulated in the presence of

stress or infection, leading to cytotoxicity by binding to the NK Gene 2D (NKG2D) receptor or by direct recognition [65]. In addition,  $\gamma\delta$ T-lymphocytes also express pattern recognition receptors (PPR), such as Toll-like receptors (TLR) that modulate their activation.  $\gamma\delta$ T-lymphocytes exert their activity through a TcR-independent recognition of non-peptidic phosphorylated antigens, called phosphoantigens (PA) produced by many bacteria such as different strains of *Staphylococcus*, *Enterococcus faecalis*, *Myxococcus fulvus*, *Streptococcus mutans*, *Lactobacillus casei*, and *Lactobacillus plantarum*, or derived from the mevalonate isoprenoid pathway [66].  $\gamma\delta$ T-lymphocytes express CD16 (FC $\gamma$ RIII) receptor, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) [67]. In hematological malignancies, large inter-individual variations in the expansion capacity of  $\gamma\delta$ T-lymphocytes have been observed among different patients having multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and CLL [68]. Our group has demonstrated that  $\gamma\delta$ T-lymphocytes could be amplified by both biphosphonates and IL2, and in vitro observations have shown that these allogeneic cells could kill both human MM cell lines and fresh myeloma tumoral cells from patients [69]. The anti-tumor effect of  $\gamma\delta$ T-lymphocytes has been mainly demonstrated in lymphoid malignancies [70, 71]. Two strategies have been applied, including adoptive cell transfer after in vitro expansion, particularly used in solid cancers, and in vivo therapeutic activation of  $\gamma\delta$ T-lymphocytes by PA or aminobiphosphonates with low dose IL-2 that has been preferentially used in hematological malignancies. Using both therapeutic strategies, the response rate was variable due to the limited number of patients included in these studies but the clinical benefit was observed when combined with other treatments, for instance, AlloT [72].

To demonstrate that  $\gamma\delta$ T-lymphocytes are also amplified in vivo, we have conducted a multicenter phase II clinical study comprising of 45 patients who presented with advanced FL in relapse or refractory relapse, since last line of therapy, with a median time of 19.1 months [Protocol No. IPH1 101-202, EudraCT No. 2006-006891-39, presented at EHA 2010;95:p10]. The patients received bromohydrin pyrophosphate (BrHPP, named IPH1101 from Innate Pharma Inc. Marseille, France), at 750 mg/m<sup>2</sup> 3 times every 3 weeks, low dose IL2 (8 MIU, daily for 5 days, every 3 weeks) and rituximab (375 mg/m<sup>2</sup>, 4 times weekly) by intravenous route. The median age of the patients was 59 years (range 39–74 years), and 47% of them had a low FLIPI and 27% had high FLIPI. Selective amplification of targeted CD16<sup>+</sup>  $\gamma\delta$ T-lymphocytes was observed, peaking after the first cycle of therapy (Fig. 1a). No amplification of the Treg lymphocytes was observed, but they demonstrated a tendency to increase slightly after the third cycle of the treatment. The



objective response rate (ORR) was 47.4%, with the highest ORR observed in patients with low FLIPI (Fig. 1b). The tolerance was satisfactory, with 90% of the adverse events being grade 1–2, possibly due to the use of IL2. No biomarker was correlated to clinical response, except a concentration of rituximab superior to 25,000 ng/mL at day-86 as previously reported [73, 74]. In vitro synergism of  $\gamma\delta$ T-lymphocytes was also observed with a new generation of anti-CD20 mAbs like obinutuzumab [75]. We observed that  $\gamma\delta$ T-lymphocytes were able to amplify the activity of other immune cells, particularly the NK lymphocytes and dendritic cells (DC) [76, 77]. These results showed the efficacy and non-toxic effects of  $\gamma\delta$ T-lymphocytes to shrink tumor mass, possibly due to their

non-MHC-restriction with no graft versus host (GVH) effect, thereby leading to the opportunity for new clinical trials regarding the CAR  $\gamma\delta$ T-lymphocytes [78].

### NK lymphocytes

Natural killer lymphocytes are defined as CD3<sup>-</sup> CD56<sup>+</sup> lymphocytes, with different circulating subpopulations, particularly CD56<sup>bright</sup> and CD56<sup>dim</sup> lymphocyte subsets. NK lymphocytes can rapidly kill target cells independently to prior immunization or MHC restriction, rendering these cells attractive for immune therapy [79]. This activation process is regulated by a balanced mechanism between the inhibitory and activating signals from different receptors, including NK cytotoxicity receptors (NCR), C-type lectin receptors (NKG2A/B, NKG2C, NKG2D, NKG2F) and killer immunoglobulin-like receptors (KIR) [79], leading to greater responsiveness to subsequent activation stimuli through a process called NK cell licensing [80, 81], with the possible generation of long-lived memory cells [82]. More than 740 clinical trials, corresponding to different origins of the NK, from peripheral blood, umbilical cord blood, progenitors or NK-92 cell line [83], with different modes of amplification/activation of autologous or Allo- (including haplo-identical) NK, are referred at the NIH. The first clinical trial with NK lymphocytes was based on autologous amplified NK lymphocytes by using in vivo cytokines, i.e., IL2, IL12, IL15, IL18, IL21 and type I interferon (IFN) [84]. By using such stimulations, cells became LAK, or CIK if  $\gamma$ IFN was added to the culture conditions 24 h before stimulation by anti-CD3 with IL2 [85, 86]. CIKs are represented by a mixture of T-cells, NK T-cells and NK lymphocytes which particularly express CD16, CD45RA, CR7, CD27, CD28. The number of cytotoxic cells needed for lysing tumor cells is  $2 \times 10^{11}$  for LAK and only  $0.5\text{--}5 \times 10^{10}$  for CIKs [87]. Cytotoxic T-cells are effective against cancer cells, but also responsible for graft-versus-host disease (GVHD) effect. In Allo cellular products, the minimal contamination of T-cells to avoid GVHD has been defined from Allo bone marrow transplantation at lower than  $1 \times 10^3/\text{kg}$  [88].

Autologous NK lymphocytes have been used in both solid and hematological malignancies with minor clinical efficacy but demonstrated better efficacy with haplo-identical-Allo NK lymphocytes [89, 90]. As such, haplo-identical or AlloNK lymphocytes (usually with KIR-mismatch) were mainly administered with AlloT lymphocytes in hematological malignancies, or in combination with mAbs (i.e., rituximab, trastuzumab, antiGD2 F8, elotuzumab). Different amplification/activation procedures were used, with cytokines (IL2, IL12, IL15, IL15, and IL21) with or without K562-m15-41BB ligand engineered cell line as feeder cells, generally

using CD56-selection and/or CD3/CD19 depletion and followed by in vivo cytokine administration (IL2 or IL15) or IL2DT fusion protein to deplete Treg that express high amount of IL2R  $\alpha$  chain [90]. To activate autologous NK in vivo, other therapeutic procedures have been developed by using an anti-KIR mAb with no clinical efficacy when used alone, or by inhibiting disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) to improve CD16 expression [91–93]. In most of the clinical trials, NK cell-drugs were prepared from a donor to a recipient. Umbilical cord blood offers the possibility to obtain NK cellular products from progenitor CD34<sup>+</sup> cells as shown by Glycostem Inc. (Hertogenbosch, Netherland), or by amplifying and activating mixture of naive NK lymphocytes from the umbilical cord blood [94]. CAR-NK have been developed in pre- and early clinical studies, with redirected human NK and NK-92 cell line, against CD19, CD20, CD38, CD138, CD244, human epithelial growth receptor (HER) 2, disialoganglioside (GD) 2, epithelial cell adhesion molecule (EPCAM), CCND3 Subset (CS)1, lectin, mannose-binding (LMAN)1 [95, 96].

Due to their capacity for killing cancer cells, the use of activated NK and CAR-NK lymphocytes represent an attractive anti-cancer cell-drug for both hematological malignancies and solid tumors.

### NKT lymphocytes


NKT cells are a subpopulation of lymphocytes possessing the phenotypic properties of both T- and NK-lymphocytes, which makes them attractive for immune therapy. Invariant NKT, also named as type I NKT, lymphocytes expressed specific TcR that recognizes lipid antigens presented by the conserved and non-polymorphic MHC class I like molecule CD1d and receptors for cytokines such as IL2, IL8, IL23 and IL25 [97]. Several drugs have been generated for triggering these cells through CD1d molecules, including  $\alpha$ -galactosylceramides synthetic analogs, but no major clinical effect was observed [98]. To direct cancer cell lysis, invariant NKT lymphocytes was used to activate both innate and adaptive immune cells in the tumor microenvironment, through the secretion of cytokines, such as Th1-, Th2- and Th17-type responses, particularly the  $\gamma$ -chain cytokine or CD132 (i.e., IL2, IL4, IL7, IL9, IL15 and IL21-R). In addition, the adoptive transfer of type I NKT lymphocytes generated in vitro from autologous lymphocytes or from Allo-CD34 progenitors cells isolated from umbilical cord blood using IL15 and stem cell factor in preclinical models have demonstrated promising results [99].

### Activation of IEC and restoring anti-tumor immune functions


#### Activation of IEC's anti-tumor effect by DCs

Mature autologous DCs are professional APC, generated from mononuclear cells (MC) by using a cocktail of cytokines [100]. DC stimulated specific CD8 positive cells against TSA. Autologous DC pulsed with TAA or cell lysates have been obtained ex vivo, with the expression of different surface markers and the secretion of diverse cytokines and chemokines, as previously described [101] and illustrated in Fig. 2. In metastatic prostate cancer, activated and pulsed DCs have been generated ex vivo from autologous MC, by using a prostatic acid phosphatase-granulocyte macrophage colony stimulating factor (GM-CSF) fusion protein, the Sipuleucel-T. This cellular product was used in

a randomized study, demonstrating a 4.1-month in median survival difference observed in favor of the vaccination arm as compared to the control arm [102]. Vaccination programs using TSA alone or DC-pulsed with TSA have been extensively used in different cancers, particularly using idiotype shared by cancer cells in FL, but with little clinical benefits [103–105]. As the multitargeting approach is considered to be more active against cancer cells, we used DC-based therapy pulsed with tumor cell lysates in a phase II study for patients in relapse having FL [106]. A specific response was demonstrated after intra-dermal injections (Fig. 3a, b). Eleven patients were treated, of whom two had complete responses (CR) before vaccination and 2 had CR after the vaccination program. An early (15 days after vaccination) [18F] fluorodeoxyglucose-positron emission tomography was performed in one patient, and it



**Fig. 2** Ex vivo maturation and differentiation of dendritic cells (DC) from monocytes. Mononuclear cells were collected by apheresis from the patient. These mononuclear cells were differentiated ex vivo to immature DC in the presence of GM-CSF and IL4 or IL13. The mature DCs were obtained after stimulation by TNF- $\alpha$  and they exhibited different biomarkers, such as CD86, CD80, CCR7, and the antigen-MHC complex. GM-CSF: Granulocyte-Macrophage Colony Stimulating Factor; IL: interleukin; TNF: Tumor Necrosis Factor; MHC: major histocompatibility complex; CTL: cytotoxic lymphocytes; CCR: C-C chemokine receptor; Ag: antigen;  $\alpha_v$ : integrin alpha V;  $\beta_5$ : integrin beta 5; CTL: cytotoxic lymphocytes; DC: dendritic cells; FcR: Fc receptor; Poly-IC: polycytidylic acid; RNA: ribonucleic acid



**Fig. 3** A phase II clinical trial with DC pulsed with tumoral cell lysates from patients having follicular lymphoma. **a** Intradermal injection of 0.2 mL of DC-pulsed with tumoral lysates ( $5 \times 10^6$  DC/mL) (5 sites) and KLH intradermal injection (100  $\mu$ g in 0.2 mL) used as a control. Magnification:  $\times 1$ ; **b** Delayed hypersensitivity after intradermal injections (1) and cutaneous biopsies (2) showing important CD3 positive infiltrate and CD68 positive macrophages; **c** [18F] fluorodeoxyglucose-positron emission tomography scanning (FDG pet-scan): (1) before vaccination with tumoral lymph node (yellow arrow), (2) 15 days after the vaccination with increased hypermetabolism of the lymph node (white arrow), (3) 2 months after the vaccination with the disappearance of the hypermetabolism (yellow arrow), suggesting an activation of the IECs within the lymph node. 1: injection site with 0.2 mL of DC-pulsed with tumoral lysates; 2: injection site of control; DC: dendritic cells; KLH: Keyhole limpet hemocyanin

showed an early metabolic activation in the lymph node (Fig. 3c), that may constitute an early clinical indicator of the efficacy among the immunomonitoring.

Clinical responses regarding the use of DCs have been disappointing, with an ORR of around 15% [107]. Improvements may include the use of immune adjuvants that improve the antigen delivery as mineral salts, emulsions, and liposomes, or immunostimulants such as TLR-ligands (particularly TLR7/8 agonists such as the imidazoquinoline family [108], cytokines, saponins, bacterial exotoxins and exosomes [109–112]. Recently, boosting the capture and presentation of TAA were developed by using hydroxylapatite combined to tumor extract containing HSP from a frozen sample after thawing, then subcutaneously injected, disposal named APAVAC<sup>®</sup> (URODELIA Inc, Toulouse France) [113]. A randomized placebo-controlled double-blinded chemo-immunotherapy clinical trial was conducted in a pet dog model of diffuse large b-cell lymphoma using APAVAC<sup>®</sup>. The median time to progression and median lymphoma-specific survival were significantly different in dogs having chemo-immunotherapy vs. chemotherapy alone; 304 days vs. 41 days ( $P=0.0004$ ) and 505 days vs. 159 days ( $P=0.0018$ ), respectively [114]. Preliminary data in humans have been published with promising data in advanced cancers as shown by Ciocca et al. [113].

The efficiency of DC migration from the skin to the lymph nodes has been studied and is linked to the maturation status and the C–C chemokine receptor (CCR) 7 expression of the DCs [115]. Recently, a pilot clinical trial was reported with a personalized vaccine generated by autologous DCs pulsed with whole-tumor cell lysate in patients having ovarian cancer [116]. This vaccine elicited efficiently a broad antitumor immunity, including private neo-antigens. Tumor cells eradication has been achieved by using in situ vaccination with a TLR ligand and anti-OX-40 antibody in an animal model [116].

Important interactions between IECs has led to an amplified or synergistic activity among the different immune therapies supporting combined therapies. The aim of such combined strategies is to amplify specific recognition to reinforce the killing activity or to lower immune suppressive effect. TAA or MHC class I expression at the cell surface of cancer cells could be reinforced by epigenetic modulation or by interfering on metabolism pathways [23, 30, 31, 117]. Cell crosstalk is essential for immune therapy. Subsets of CD56<sup>bright</sup>CD16<sup>dim/-</sup> NK lymphocytes present in lymph nodes possess helper role in the production of  $\gamma$ IFN that may improve the DC activity [118]. By combining mAbs and certain cytokines that activate DCs, we observed a delayed but progressive clinical response which may be explained by an in vivo vaccination process, as suggested in one patient treated


by rituximab and GM-CSF [119] (Fig. 4). This observation suggested that rituximab possibly enhances the apoptosis of tumor cells, and GM-CSF participates to in vivo generation of mature DC and may prolong disease immune control.

### Blocking the immune suppression source of cancer cells

The T-cells can be activated by two signals in normal physiology. One when the T-cell receptor is bounded to an antigen-MHC or second, when the T-cell surface receptor, CD28, binds to CD80/CD86 proteins [120]. CTLA4 inhibits the binding of CD80/CD86 to CD28 and negatively regulate the activation of T-cells. The immune response can be enhanced by blocking immune checkpoints shared by T-cells with the presence of their ligands on both cancer cells and DCs (Fig. 5) [121, 122]. The expression of immune checkpoints by TIL, and particularly Treg, results in low responsiveness of the immune control of cancer cells. Thereby, targeting these markers are very attractive targets for reversing immune tolerance, particularly in cancer. The anti-CTLA-4 mAb, ipilimumab, received the FDA approval in March 2011 for the treatment of metastatic melanoma [123], metastatic renal cell carcinoma, and non-small cell lung carcinoma [124], as it has shown efficacy in causing a shift increase in the number of cytotoxic T-cells to enhance anti-tumor response. Further development is ongoing in both solid tumors and hematological malignancies with different molecules (MDX-1106 or nivolumab, and CT-011 or pidilizumab as anti-PD-1; MDX-1105 as anti-PD-L1, and other molecules directed against T-cell Immunoglobulin and mucin domain-containing protein 3 [Tim-3], lymphocyte activation gene-3 [LAG-3], and V-domain Ig-containing suppressor of T-cell activation [VISTA]). More than 92 clinical trials regarding immune checkpoint inhibitors are now referred at the NIH [125].


### Defining the therapeutic strategy

The therapeutic strategy must be clearly defined based upon proper analysis regarding the characteristics of the cancer cells, the tumor-host microenvironment, and the immune system status of the patient. Different therapeutic options are available aiming to stimulate IEC activity, to block immune checkpoints or immune cells that favor cancer cell growth. Lymphodepletion is generally used to modify the host microenvironment, particularly to limit the Treg activity [126]. This can be achieved by giving total body irradiation, non-myeloablative chemotherapy as conditioning regimen for AlloT or prescribing a low dose of chemotherapy such as cyclophosphamide, 5-fluorouracil, fludarabine, gemcitabine, bortezomib, sorafenib and sunitinib [127].



Other targeted therapies have been described to have an immune effect. Recently, idelalisib, an inhibitor of phosphoinositide 3 kinase  $\delta$  [128] has been mentioned to be able to deplete Treg and myeloid-derived suppressor cells [129], and ibrutinib, to favor

antigen presentation [130]. Other therapeutic strategies have been developed, including molecules targeting Treg, such as anti-CD25 molecules, anti-Foxp3 or anti-CTLA4, inhibitors of STAT3 that regulates the




expression of TGF- $\beta$  and IL10 cytokines or inhibitors of indoleamine 2,3-dioxygenase [127, 131].

Strategy for Immune therapy requires choosing the best immune therapeutic tools at the right time, as suggested in Fig. 6. In addition, a combination of immune and standard treatments is also crucial, meaning that radiotherapy or chemotherapy may favor the circulation of neoantigens generated after cancer cell killing, to be collected for vaccine programs. After high dose therapy in patients having MM, our group has described a burst of cytokines, particularly of IL7/IL15 at day-8 and IL6 at day-15 [132]. Autologous transplantation offers another “window” of opportunity for using IECs. High dose therapy followed by autologous transplantation is generally associated with the induction of a pre-apoptotic status for both the tumor cells and the CD3 positive cells that could be saved by cytokine peaks. This opens two therapeutic opportunities. One, to block IL6 which is the survival/proliferation factor of MM cells, as described in one

of our previous study [133], and/or second, to administer activated/amplified IEC after high dose therapy, including  $\gamma\delta$ T, NK, or CAR-T lymphocytes [134]. Similarly, AlloT and particularly haplo-identical AlloT are considered as a model for immune therapy.

### Conclusion

Immune precision medicine is a complex medical trail, starting from a careful personalized evaluation of the characteristics of the cancer cell and the conditions of the cancer-host microenvironment as well as the bio-clinical status of the host. Personalized evaluation of the disease opens the way to identify the optimal therapeutic strategy. The aim is to reinforce the IECs that kill cancer cells and to decrease those factors that favor cancer cell growth. These can be achieved, in a dynamic way, by administering IECs such as CAR-lymphocytes, to kill tumor cells. Then, the immune system could be challenged to eradicate residual disease with vaccination



**Fig. 6** Time-windows of opportunity in immune therapy for cancers. After tumor mass reduction by chemotherapy, there is a burst of cytokines and lymphodepletion that are benefitting for in vivo activity of the immune effector cells such as NK or  $\gamma\delta$  T-lymphocytes. CAR-T cells are engineered cytotoxic T-cells that could be used instead of chemotherapy when chemoresistance is observed or to complete tumor cell killing. To control residual disease, repetitive administration of immune effector cells could be proposed. Immune checkpoint inhibitors are potent immune adjuvants to be combined for amplifying the T-cell response, probably at a lower dose and to avoid immune exhaustion. The role of vaccine using neoantigens is probably an alternative therapy for frail patients and this represents a good opportunity to challenge the immune specific functions along with the immune control of the tumor. IEC: immune effector cells; CAR-T: chimeric antigen receptor T-cell therapy; MRD: minimal residual disease; PR: partial response, CR: complete response

whose activity can be amplified by inhibitors of immune checkpoints and/or immune adjuvants. Based on such, we firmly believe that immune precision medicine is internal medicine with modern tools that are beneficial for improving the treatment and outcomes of cancer patients.

**Abbreviations**

ADAM-17: disintegrin and metalloproteinase domain-containing protein 17; ADCC: antibody-dependent-cell cytotoxicity; AlloT: allogeneic transplantation; APC: antigen presenting cell; BrHPP: bromohydrin pyrophosphate; CAR: chimeric antigen receptor; CCR7: C–C chemokine receptor 7; CD: cluster of differentiation; CIK: cytokine induced killer; CLL: chronic lymphocytic leukemia; CR: complete response; CRP: C reactive protein; CS1: CCND3 subset 1; CTL: cytotoxic T-lymphocytes; CTLA-4: cytotoxic T-lymphocyte antigen-4; DC: dendritic cell; DLI: donor lymphocyte infusion; EPCAM: epithelial adhesion molecule; ERK 5: extracellular-signal-regulated kinase 5; FDA: Food and Drug Administration; FLIPI: Follicular Lymphoma Prognostic Index; GD2: disialoganglioside 2; GMCSF: granulocyte macrophage colony stimulating factor; GVHD: graft versus host disease; HER2: human epithelial growth receptor 2; HSP: heat shock protein; IEC: immune effector cells; IFN: interferon; IL: interleukin; IR: inhibitory receptors; IV: intravenous; LAK: lymphocyte activated killer; LMAN1: lectin mannose binding 1; mAb: monoclonal antibody; MHC: major histocompatibility complex; MPE: molecular pathological epidemiology; MM: multiple myeloma; NHL: non-Hodgkin’s lymphoma; NIH: National Institute of Health; NK: natural killer; ORR: overall response rate; PA: phosphoantigens; PD:

programmed cell death; PDL: PD ligand; PPR: pattern recognition receptors; TAA: tumor associated antigen; TcR: T-cell receptor; TGF: transforming growth factor; TIL: tumor infiltrating lymphocyte; TLR: Toll-like receptor; TNF: Tumor Necrosis Factor; Treg: T-regulator.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JFR had the idea of the article and he wrote this paper. PC was a contributing author in revising the manuscript and is particularly active in the domain of allogeneic immune therapy. ZYL is particularly implicated in biotherapy and he reviewed this article. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

All the clinical data reported in this article are unpublished data from clinical research programs that have been performed in accordance with the Declaration of Helsinki and have been approved by the ethics committee Sud-Méditerranée II (Marseille, France for Protocol No. IPH1 101-202, EudraCT No. 2006-006891-39) including the patients written consent to participate.

**Consent for publication**

Consent for publication was obtained from all the authors.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

<sup>1</sup> Institut Sainte Catherine, 84918 Avignon, France. <sup>2</sup> Université Montpellier 1, UFR Médecine, 34396 Montpellier, France. <sup>3</sup> Département d'Hématologie, CHU de Montpellier, 34295 Montpellier, France. <sup>4</sup> Unité de Thérapie Cellulaire, CHU Saint-Eloi, 34295 Montpellier, France.

Received: 31 May 2018 Accepted: 3 June 2019

Published online: 14 June 2019

**References**

- Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology—analysis of host and tumor factors for personalized medicine. *Nat Rev Clin Oncol*. 2011;8(12):711–9. <https://doi.org/10.1038/nrclinonc.2011.122>.
- Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. *J Gastroenterol*. 2017;52(3):265–75. <https://doi.org/10.1007/s00535-016-1272-3>.
- Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut*. 2011;60(3):397–411. <https://doi.org/10.1136/gut.2010.217182>.
- U.S. National Library of Medicine. What is precision medicine? <https://ghr.nlm.nih.gov/primer/precisionmedicine/definition>. Accessed 16 May 2019.
- Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, et al. Words matter: distinguishing “personalized medicine” and “biologically personalized therapeutics”. *J Natl Cancer Inst*. 2014. <https://doi.org/10.1093/jnci/dju321>.
- Shariat SF, Gust KM. Immune therapy meets precision medicine. *Lancet Oncol*. 2017;18(3):271–3. [https://doi.org/10.1016/s1470-2045\(17\)30098-0](https://doi.org/10.1016/s1470-2045(17)30098-0).
- La Porta CAM, Zapperi S. Complexity in cancer stem cells and tumor evolution: toward precision medicine. *Semin Cancer Biol*. 2017;44:3–9. <https://doi.org/10.1016/j.semcancer.2017.02.007>.
- Burnet FM. The concept of immunological surveillance. *Prog Exp Tumor Res*. 1970;13:1–27.
- Thomas L. On immunosurveillance in human cancer. *Yale J Biol Med*. 1982;55(3–4):329–33.
- Corthay A. Does the immune system naturally protect against cancer? *Front Immunol*. 2014;5:197. <https://doi.org/10.3389/fimmu.2014.00197>.
- Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the *Streptococcus erysipelas* and the *Bacillus prodigiosus*). *Proc R Soc Med*. 1910;3(Surg Sect):1–48.
- Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. *Cancer Res*. 2016;76(22):6445–51. <https://doi.org/10.1158/0008-5472.can-16-1311>.
- Mittal S, Marshall NA, Barker RN, Vickers MA. Immunomodulation against leukemias and lymphomas: a realistic future treatment? *Crit Rev Oncol/Hematol*. 2008;65(2):101–8. <https://doi.org/10.1016/j.critrevonc.2007.05.004>.
- Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. *Bone Marrow Transplant*. 2003;31(4):253–61. <https://doi.org/10.1038/sj.bmt.1703811>.
- Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. *J Cell Sci*. 2012;125(Pt 23):5591–6. <https://doi.org/10.1242/jcs.116392>.
- Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, et al. Targeting the microenvironment in solid tumors. *Cancer Treat Rev*. 2018;65:22–32. <https://doi.org/10.1016/j.ctrv.2018.02.004>.
- Saifi M, Maran A, Raynaud P, Picot MC, Quittet P, Cartron G, et al. High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. *Exp Ther Med*. 2010;1(6):933–8. <https://doi.org/10.3892/etm.2010.146>.
- Michiels C, Tellier C, Feron O. Cycling hypoxia: a key feature of the tumor microenvironment. *Biochem Biophys Acta*. 2016;1866(1):76–86. <https://doi.org/10.1016/j.bbcan.2016.06.004>.
- Zimna A, Kurpisz M. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies. *Biomed Res Int*. 2015;2015:549412. <https://doi.org/10.1155/2015/549412>.
- Axelrod ML, Cook RS, Johnson DB, Balko JM. Biological consequences of MHC-II expression by tumor cells in cancer. *Clin Cancer Res*. 2019;25(8):2392–402. <https://doi.org/10.1158/1078-0432.ccr-18-3200>.
- Vahidian F, Duijff PHG, Safarzadeh E, Derakhshani A, Baghbazadeh A, Baradaran B. Interactions between cancer stem cells, immune system and some environmental components: friends or foes? *Immunol Lett*. 2019;208:19–29. <https://doi.org/10.1016/j.imlet.2019.03.004>.
- Srivastava PK, Duan F. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. *Cancer Immunol Immunother*. 2013;62(5):967–74. <https://doi.org/10.1007/s00262-013-1422-x>.
- Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. *Ann Transl Med*. 2016;4(14):262. <https://doi.org/10.21037/atm.2016.06.17>.
- Cai W, Zhou D, Wu W, Tan WL, Wang J, Zhou C, et al. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications for prognostic immunological biomarker and vaccine design. *BMC Genom*. 2018;19(1):582. <https://doi.org/10.1186/s12864-018-4958-5>.
- Highlights of prescribing information. KEYTRUDA® (pembrolizumab) for injection, for intravenous use. [https://www.accessdata.fda.gov/drugs\\_atfda\\_docs/label/2017/125514s014bl.pdf](https://www.accessdata.fda.gov/drugs_atfda_docs/label/2017/125514s014bl.pdf). Accessed 16 May 2019.
- Yang L, Lin PC. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. *Semin Cancer Biol*. 2017;47:185–95. <https://doi.org/10.1016/j.semcancer.2017.08.001>.
- Destassis S, Grasso M, Del Vescovo V, Denti MA. microRNAs make the call in cancer personalized medicine. *Front Cell Dev Biol*. 2017;5:86. <https://doi.org/10.3389/fcell.2017.00086>.
- Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. *Nat Immunol*. 2017;18(8):851–60. <https://doi.org/10.1038/ni.3780>.
- Destexhe E, Prinsen MK, van Scholl I, Kuper CF, Garçon N, Veenstra S, et al. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. *J Pharmacol Toxicol Methods*. 2013;68(3):367–73. <https://doi.org/10.1016/j.vascn.2013.04.003>.
- Palmer CS, Hussain T, Duette G, Weller TJ, Ostrowski M, Sada-Ovalle I, et al. Regulators of glucose metabolism in CD4(+) and CD8(+) T cells. *Int Rev Immunol*. 2016;35(6):477–88. <https://doi.org/10.3109/08830185.2015.1082178>.
- Catalan E, Charni S, Jaime P, Aguilo JI, Enriquez JA, Naval J, et al. MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. *Oncoimmunology*. 2015;4(1):e985924. <https://doi.org/10.4161/2162402x.2014.985924>.
- Pampena MB, Cartar HC, Cueto GR, Levy EM, Blanco PA, Barrio MM, et al. Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants. *Front Immunol*. 2018;9:2531. <https://doi.org/10.3389/fimmu.2018.02531>.
- Kawamura J, Sugiura F, Sukegawa Y, Yoshioka Y, Hida JI, Hazama S, et al. Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer. *Oncol Lett*. 2018;15(4):4241–7. <https://doi.org/10.3892/ol.2018.7905>.
- Obara W, Hara I, Kato Y, Kato R, Inoue K, Sato F, et al. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer. *Cancer Immunol Immunother*. 2018;67(9):1371–80. <https://doi.org/10.1007/s00262-018-2197-x>.
- Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. *Int J Cancer*. 2017;140(4):973–82. <https://doi.org/10.1002/ijc.30510>.
- Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, et al. A randomized phase II clinical trial of personalized peptide vaccination

- with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. *Cancer Immunol Immunother.* 2016;65(2):151–60. <https://doi.org/10.1007/s00262-015-1781-6>.
37. Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. *Breast Cancer Res.* 2014;16(4):R70. <https://doi.org/10.1186/bcr3685>.
  38. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. *Clin Cancer Res.* 2013;19(8):2224–31. <https://doi.org/10.1158/1078-0432.ccr-12-3592>.
  39. Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, Mizuguchi J. Interleukins and cancer immunotherapy. *Immunotherapy.* 2009;1(5):825–44. <https://doi.org/10.2217/imt.09.46>.
  40. Humphries C. Adoptive cell therapy: honing that killer instinct. *Nature.* 2013;504(7480):S13–5. <https://doi.org/10.1038/504513a>.
  41. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. *Nat Rev Clin Oncol.* 2011;8(10):577–85. <https://doi.org/10.1038/nrclinonc.2011.116>.
  42. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. *Cancer Res.* 2015;75(1):5–10. <https://doi.org/10.1158/0008-5472.can-14-2538>.
  43. Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X, et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. *Front Immunol.* 2017;8:774. <https://doi.org/10.3389/fimmu.2017.00774>.
  44. Stavrou D, Bilzer T, Anzil AP, Hulten M, Kaldrymidou E. Reactivity of tumor-infiltrating, blood, spleen and lymph node lymphocytes against syngeneic glioma target cells. *Anticancer Res.* 1981;1(3):125–34.
  45. Lloyd KO. Tumor antigens known to be immunogenic in man. *Ann NY Acad Sci.* 1993;690:50–8.
  46. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. *Immunol Rev.* 1995;145:61–89.
  47. Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. *Immunol Invest.* 2016;45(7):619–40. <https://doi.org/10.1080/08820139.2016.1197241>.
  48. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. *J Intern Med.* 2012;271(2):183–92. <https://doi.org/10.1111/j.1365-2796.2011.02496.x>.
  49. Heninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. *Front Immunol.* 2015;6:29. <https://doi.org/10.3389/fimmu.2015.00029>.
  50. Kortenhorst MS, Wissing MD, Rodriguez R, Kachhap SK, Jans JJ, Van der Groep P, et al. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. *Epigenetics.* 2013;8(9):907–20. <https://doi.org/10.4161/epi.25574>.
  51. Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. *Int Rev Immunol.* 2015;34(2):154–87. <https://doi.org/10.3109/08830185.2015.1018419>.
  52. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. *Blood.* 2013;122(18):3138–48. <https://doi.org/10.1182/blood-2012-12-474056>.
  53. Zou Y, Xu W, Li J. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. *J Hematol Oncol.* 2018;11(1):130. <https://doi.org/10.1186/s13045-018-0676-3>.
  54. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med.* 2013;368(16):1509–18. <https://doi.org/10.1056/NEJMoa1215134>.
  55. Park JH, Riviere I, Gonen M, Wang X, Seneschal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med.* 2018;378(5):449–59. <https://doi.org/10.1056/NEJMoA1709919>.
  56. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther.* 2010;18(4):843–51. <https://doi.org/10.1038/mt.2010.24>.
  57. Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood.* 2017;130(21):2295–306. <https://doi.org/10.1182/blood-2017-06-793141>.
  58. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. *Hematol Am Soc Hematol Educ Progr.* 2016;2016(1):567–72. <https://doi.org/10.1182/asheducation-2016.1.567>.
  59. U.S. National Library of Medicine. *ClinicalTrials.gov*. <https://clinicaltrials.gov/ct2/results?term=CART-cells&Search=Search>. Accessed 16 May 2019.
  60. Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR-T cell therapies for B-cell malignancies. *Front Oncol.* 2019;9:146. <https://doi.org/10.3389/fonc.2019.00146>.
  61. Schutz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. *Cancer Gene Ther.* 2001;8(9):655–61. <https://doi.org/10.1038/sj.cgt.7700351>.
  62. Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, et al. Plasticity of gammadelta T cells: impact on the anti-tumor response. *Front Immunol.* 2014;5:622. <https://doi.org/10.3389/fimmu.2014.00622>.
  63. He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, et al. Gammadelta T cell and other immune cells crosstalk in cellular immunity. *J Immunol Res.* 2014;2014:960252. <https://doi.org/10.1155/2014/960252>.
  64. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. *J Exp Med.* 2003;197(2):163–8. <https://doi.org/10.1084/jem.20021500>.
  65. Poggi A, Zocchi MR. Gammadelta T lymphocytes as a first line of immune defense: old and new ways of antigen recognition and implications for cancer immunotherapy. *Front Immunol.* 2014;5:575. <https://doi.org/10.3389/fimmu.2014.00575>.
  66. Dunne MR, Mangan BA, Madrigal-Estebas L, Doherty DG. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vgamma9Vdelta2 T cells. *Mediat Inflamm.* 2010;2010:704941. <https://doi.org/10.1155/2010/704941>.
  67. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. *J Immunol.* 2001;166(12):7190–9.
  68. Wesch D, Peters C, Siegers GM. Human gamma delta T regulatory cells in cancer: fact or fiction? *Front Immunol.* 2014;5:598. <https://doi.org/10.3389/fimmu.2014.00598>.
  69. Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. *Br J Haematol.* 2007;139(2):206–16. <https://doi.org/10.1111/j.1365-2141.2007.06754.x>.
  70. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, et al. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial. *J Immunother.* 2012;35(2):205–13. <https://doi.org/10.1097/cji.0b013e318245bb1e>.
  71. Paul S, Lal G. Regulatory and effector functions of gamma-delta (gammadelta) T cells and their therapeutic potential in adoptive cellular therapy for cancer. *Int J Cancer.* 2016;139(5):976–85. <https://doi.org/10.1002/ijc.30109>.
  72. Hoeres T, Smetak M, Pretschner D, Wilhelm M. Improving the efficiency of Vgamma9Vdelta2 T-cell immunotherapy in cancer. *Front Immunol.* 2018;9:800. <https://doi.org/10.3389/fimmu.2018.00800>.
  73. Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. *mAbs.* 2013;5(6):826–37. <https://doi.org/10.4161/mabs.26008>.
  74. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. *J Clin Oncol.* 1999;17(6):1851–7. <https://doi.org/10.1200/jco.1999.17.6.1851>.

75. Braza MS, Klein B, Fiol G, Rossi JF. gammadelta T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. *Haematologica*. 2011;96(3):400–7. <https://doi.org/10.3324/haematol.2010.029520>.
76. Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. *Front Immunol*. 2014;5:636. <https://doi.org/10.3389/fimmu.2014.00636>.
77. Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. *Br J Haematol*. 2013;160(2):123–32. <https://doi.org/10.1111/bjh.12090>.
78. Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. *Mol Ther*. 2018;26(2):354–65. <https://doi.org/10.1016/j.jymthe.2017.12.001>.
79. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends Immunol*. 2001;22(11):633–40.
80. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. *Immunity*. 2006;25(2):331–42. <https://doi.org/10.1016/j.immuni.2006.06.013>.
81. Thomas LM, Peterson ME, Long EO. Cutting edge: NK cell licensing modulates adhesion to target cells. *J Immunol*. 2013;191(8):3981–5. <https://doi.org/10.4049/jimmunol.1301159>.
82. Rolle A, Pollmann J, Cerwenka A. Memory of infections: an emerging role for natural killer cells. *PLoS Pathog*. 2013;9(9):e1003548. <https://doi.org/10.1371/journal.ppat.1003548>.
83. Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy—advantages of the NK-92 Cell line over blood NK cells. *Front Immunol*. 2016;7:91. <https://doi.org/10.3389/fimmu.2016.00091>.
84. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. *Cell Mol Immunol*. 2013;10(3):230–52. <https://doi.org/10.1038/cmi.2013.10>.
85. Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. *J Immunol*. 1987;138(8):2728–33.
86. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. *J Transl Med*. 2013;11:83. <https://doi.org/10.1186/1479-5876-11-83>.
87. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med*. 1991;174(1):139–49. <https://doi.org/10.1084/jem.174.1.139>.
88. Muller S, Schulz A, Reiss U, Schwarz K, Schreiner T, Wiesneth M, et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. *Bone Marrow Transplant*. 1999;24(6):575–81. <https://doi.org/10.1038/sj.bmt.1701970>.
89. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. *J Clin Oncol*. 2010;28(6):955–9. <https://doi.org/10.1200/jco.2009.24.4590>.
90. Ali J, Harper I, Bolton E, Bradley JA, Pettigrew G. Recipient natural killer cell allorecognition of passenger donor lymphocytes and its effect on adaptive alloimmunity after transplantation. *Lancet*. 2015;385(Suppl 1):S18. [https://doi.org/10.1016/s0140-6736\(15\)60333-6](https://doi.org/10.1016/s0140-6736(15)60333-6).
91. Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. *Oncoimmunology*. 2016;5(4):e1115178. <https://doi.org/10.1080/2162402x.2015.1115178>.
92. Lowry LE, Zehring WA. Potentiation of natural killer cells for cancer immunotherapy: a review of literature. *Front Immunol*. 2017;8:1061. <https://doi.org/10.3389/fimmu.2017.01061>.
93. Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. *Haematologica*. 2014;99(6):e81–3. <https://doi.org/10.3324/haematol.2013.103085>.
94. Vermeris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. *Br J Haematol*. 2009;147(2):185–91. <https://doi.org/10.1111/j.1365-2141.2009.07768.x>.
95. Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. *Mol Oncol*. 2014;8(2):297–310. <https://doi.org/10.1016/j.molonc.2013.12.001>.
96. Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. *Front Immunol*. 2018;9:283. <https://doi.org/10.3389/fimmu.2018.00283>.
97. Carreno LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as vaccine adjuvants. *Immunotherapy*. 2014;6(3):309–20. <https://doi.org/10.2217/imt.13.175>.
98. Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. *Front Immunol*. 2017;8:1178. <https://doi.org/10.3389/fimmu.2017.01178>.
99. Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L. Antigen-specific vaccines for cancer treatment. *Hum Vaccines Immunother*. 2014;10(11):3332–46. <https://doi.org/10.4161/21645515.2014.973317>.
100. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature*. 1998;392(6673):245–52. <https://doi.org/10.1038/32588>.
101. Tarte K, Fiol G, Rossi JF, Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. *Leukemia*. 2000;14(12):2182–92.
102. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363(5):411–22. <https://doi.org/10.1056/NEJMoa1001294>.
103. Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. *Hematol Am Soc Hematol Educ Progr*. 2007. <https://doi.org/10.1182/asheducation-2007.1.226>.
104. Bendandi M. Anti-idiotypic vaccines for human follicular lymphoma. *Leukemia*. 2000;14(8):1333–9.
105. Thomas SK, Kwak LW. Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial. *Semin Oncol*. 2012;39(3):253–62. <https://doi.org/10.1053/j.seminoncol.2012.02.014>.
106. Baudard M, Comte F, Conge AM, Mariano-Goulart D, Klein B, Rossi JF. Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. *Leuk Lymphoma*. 2007;48(2):381–8. <https://doi.org/10.1080/10428190601094354>.
107. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. *Lancet Oncol*. 2014;15(7):e257–67. [https://doi.org/10.1016/s1470-2045\(13\)70585-0](https://doi.org/10.1016/s1470-2045(13)70585-0).
108. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. *Oncogene*. 2008;27(2):190–9. <https://doi.org/10.1038/sj.onc.1210913>.
109. Wimmers F, Schreiber T, Skold AE, Figdor CG, De Vries IJ. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. *Front Immunol*. 2014;5:165. <https://doi.org/10.3389/fimmu.2014.00165>.
110. Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. *Semin Immunol*. 2010;22(3):155–61. <https://doi.org/10.1016/j.smim.2010.04.007>.
111. Pizzurro GA, Barrio MM. Dendritic cell-based vaccine efficacy: aiming for hot spots. *Front Immunol*. 2015;6:91. <https://doi.org/10.3389/fimmu.2015.00091>.
112. Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuti JA. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. *Front Immunol*. 2014;5:692. <https://doi.org/10.3389/fimmu.2014.00692>.
113. Ciocca DR, Frayssinet P, Cuello-Carrion FD. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients. *Cell Stress Chaperones*. 2007;12(1):33–43.
114. Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P, et al. Randomized, placebo-controlled, double-blinded chemotherapeutic clinical trial in a pet dog model of diffuse large B-cell lymphoma. *Clin Cancer Res*. 2014;20(3):668–77. <https://doi.org/10.1158/1078-0432.ccr-13-2283>.
115. Sanchez-Sanchez N, Riolo-Blanco L, Rodriguez-Fernandez JL. The multiple personalities of the chemokine receptor CCR1 in dendritic cells. *J Immunol*. 2006;176(9):5153–9.
116. Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. *Sci Transl Med*. 2018. <https://doi.org/10.1126/scitranslmed.aao5931>.

117. Charni S, de Bettignies G, Rathore MG, Aguilo JI, van den Elsen PJ, Haouzi D, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. *J Immunol*. 2010;185(6):3498–503. <https://doi.org/10.4049/jimmunol.1001250>.
118. Pampena MB, Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. *Front Immunol*. 2015;6:13. <https://doi.org/10.3389/fimmu.2015.00013>.
119. Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Quittet P, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. *J Clin Oncol*. 2008;26(16):2725–31. <https://doi.org/10.1200/jco.2007.13.7729>.
120. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13(4):227–42. <https://doi.org/10.1038/nri3405>.
121. Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. *Cancer Immunol Res*. 2014;2(6):510–7. <https://doi.org/10.1158/2326-6066.cir-14-0072>.
122. Witzens-Harig M, Hose D, Junger S, Pfirschke C, Khandelwal N, Umansky L, et al. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. *Blood*. 2013;121(22):4493–503. <https://doi.org/10.1182/blood-2012-05-429415>.
123. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711–23. <https://doi.org/10.1056/NEJMoa1003466>.
124. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol*. 2017;8:561. <https://doi.org/10.3389/fphar.2017.00561>.
125. U.S. National Library of Medicine. *ClinicalTrials.gov*. <https://clinicaltrials.gov/ct2/results?term=immune+checkpoint+inhibitors+clinical+trials&Search=Search>. Accessed 16 May 2019.
126. Jackson SR, Yuan J, Teague RM. Targeting CD8+ T-cell tolerance for cancer immunotherapy. *Immunotherapy*. 2014;6(7):833–52. <https://doi.org/10.2217/imt.14.51>.
127. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death Differ*. 2014;21(1):15–25. <https://doi.org/10.1038/cdd.2013.67>.
128. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature*. 2014;510(7505):407–11. <https://doi.org/10.1038/nature13444>.
129. Medina-Echeverez J, Aranda F, Berraondo P. Myeloid-derived cells are key targets of tumor immunotherapy. *Oncoimmunology*. 2014;3:e28398. <https://doi.org/10.4161/onci.28398>.
130. Natarajan G, Oghumu S, Terrazas C, Varikuti S, Byrd JC, Satoskar AR. A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. *Oncoimmunology*. 2016;5(6):e1151592. <https://doi.org/10.1080/2162402x.2016.1151592>.
131. Liu X, Shin N, Koblisch HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. *Blood*. 2010;115(17):3520–30. <https://doi.org/10.1182/blood-2009-09-246124>.
132. Condomines M, Veyrune JL, Larroque M, Quittet P, Latry P, Lugagne C, et al. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. *J Immunol*. 2010;184(2):1079–84. <https://doi.org/10.4049/jimmunol.0804159>.
133. Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m<sup>2</sup> of melphalan in multiple myeloma: results of a pilot study including biological aspects. *Bone Marrow Transplant*. 2005;36(9):771–9. <https://doi.org/10.1038/sj.bmt.1705138>.
134. Perales MA, Sauter CS, Armand P. Fast cars and no brakes: autologous stem cell transplantation as a platform for novel immunotherapies. *Biol Blood Marrow Transplant*. 2016;22(1):17–22. <https://doi.org/10.1016/j.bbmt.2015.10.014>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

